Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
NG Bio is an early-stage investor and venture builder based in London, UK. Founded with the mission to address harmful immune responses, such as inflammation, NG Bio aims to extend human health span and longevity through innovative therapeutic solutions. The firm focuses on the life sciences sector, particularly in therapeutic development related to autoimmune diseases.
Currently, NG Bio manages a portfolio of six companies and operates with a team of four professionals. The firm engages in venture creation, providing support to its portfolio companies in financing strategies, growth, and exit planning. Their notable milestone includes the acquisition of their portfolio company, Cellesce, by Molecular Devices.
NG Bio invests primarily in the life sciences sector, with a specific emphasis on therapeutic development related to autoimmune diseases and inflammation. The firm participates in various investment stages, including pre-seed, seed, seed-plus, and Series A. Their investment strategy is centered on supporting companies that are innovating in the field of immune response and therapeutic solutions.
NG Bio seeks to partner with founders who are addressing significant health challenges through novel approaches. The organization provides comprehensive support, including assistance with financing strategies and growth planning, to ensure that portfolio companies can effectively navigate their development and exit processes.
NG Bio's portfolio includes six notable companies:
Mohammad Khobreh, MSc - Managing Partner, Co-founder. He has extensive experience in the biotech sector and has been instrumental in shaping NG Bio's investment strategy.
Jason Goldstein, MBA CA - General Partner, Co-founder. Jason brings a wealth of knowledge in venture capital and has led several successful investments in the life sciences.
Richard Kaschula, PhD - Principal. Richard specializes in therapeutic development and has a strong background in research and development within the biotech industry.
Tim Carlton, PhD - Director, Drug Development. Tim has expertise in drug development processes and plays a key role in guiding portfolio companies through their growth phases.
Startups interested in pitching to NG Bio should submit their proposals through the firm’s website at ngbio.co.uk. The pitch deck should include a comprehensive overview of the business model, market opportunity, and team qualifications. NG Bio prefers detailed information on the technology and its potential applications in the life sciences sector.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are beneficial but not mandatory for submission.
NG Bio runs a program focused on venture creation in the life sciences sector. This program supports early-stage companies in developing their therapeutic solutions and navigating the complexities of the biotech landscape.
Eligibility for the program typically includes startups that are innovating in the field of autoimmune diseases and inflammation. Interested companies can apply through NG Bio's website.
In recent months, NG Bio has been actively engaging with its portfolio companies, focusing on venture creation and support. The firm has updated its website to reflect its mission and portfolio, emphasizing its commitment to addressing harmful immune responses.
NG Bio's notable exit includes the acquisition of its portfolio company, Cellesce, by Molecular Devices, marking a significant milestone for the firm.
What are NG Bio's investment criteria?
NG Bio focuses on early-stage investments in the life sciences sector, particularly in therapeutic development related to autoimmune diseases and inflammation. They look for innovative solutions that address significant health challenges.
How can startups apply or pitch to NG Bio?
Startups can pitch to NG Bio through their website at ngbio.co.uk. It is recommended to include a detailed business plan and information about the team and technology in the pitch deck.
What makes NG Bio different from other investors?
NG Bio specializes in venture creation and provides extensive support to portfolio companies in their financing strategies, growth, and exit planning, which distinguishes them from traditional venture capital firms.
What is the geographic scope of NG Bio's investments?
NG Bio primarily invests in companies based in the United Kingdom, focusing on the life sciences sector.
What is the typical check size for investments?
NG Bio invests at various stages, including pre-seed, seed, seed-plus, and Series A, but specific check sizes are not publicly disclosed.
What kind of post-investment involvement does NG Bio have?
NG Bio actively engages with its portfolio companies, providing support in financing strategies, growth planning, and exit strategies to ensure their success.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.